These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6454488)

  • 1. Phase II study of chlorozotocin in non-small cell carcinoma of the lung.
    Cornell CJ; Hoth D; Pajak TF
    Cancer Treat Rep; 1981; 65(7-8):734-5. PubMed ID: 6454488
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ
    Cancer Treat Rep; 1979 Apr; 63(4):549-50. PubMed ID: 156068
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
    Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
    Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
    Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of streptozotocin for small cel anaplastic carcinoma of the lung.
    Kane RC; Bernath AM; Cashdollar MR
    Cancer Treat Rep; 1978 Mar; 62(3):477-8. PubMed ID: 206360
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose chlorozotocin in lung cancer: a Southwest Oncology Group Phase II Study.
    Haas CD; Stephens RL; Bukowski RM; Stuckey WJ; McCracken JD; Gagliano RG; Lehane DE; Pugh RP
    Cancer Treat Rep; 1983; 67(7-8):705-7. PubMed ID: 6223694
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
    Cancer Treat Rep; 1985 Apr; 69(4):417-20. PubMed ID: 2859924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II evaluation of chlorozotocin in refractory multiple myeloma.
    Forman WB; Cohen HJ; Bartolucci AA; Manning G
    Cancer Treat Rep; 1984 Nov; 68(11):1409-10. PubMed ID: 6238673
    [No Abstract]   [Full Text] [Related]  

  • 9. Cholestatic jaundice associated with chlorozotocin.
    Belt RJ; McGregor D; Haas CD; Bhatia PS
    Cancer Treat Rep; 1980; 64(12):1235-9. PubMed ID: 6451288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Streptozotocin: an inactive agent in small cell carcinoma.
    Maurer LH; Weiss RB; Aisner J
    Cancer Clin Trials; 1979; 2(1):59-61. PubMed ID: 229984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of chlorozotocin in patients with malignant melanoma.
    Houghton AN; Camacho FJ; Gralla RJ; Wittes R
    Cancer Treat Rep; 1981; 65(7-8):705-6. PubMed ID: 6454487
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma.
    Gralla RJ; Yagoda A
    Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222
    [No Abstract]   [Full Text] [Related]  

  • 13. Chlorozotocin (DCNU)--induced pulmonary toxicity.
    Sordillo EM; Sordillo PP; Stover D; Magill GB
    Cancer Clin Trials; 1981; 4(4):397-9. PubMed ID: 6459189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of chlorozotocin in advanced breast cancer.
    Edmonson JH; Green SJ; Ingle JN; Ahmann DL; Disel HF; Creagan ET
    Cancer Treat Rep; 1981; 65(5-6):537-8. PubMed ID: 6453648
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.
    Panasci L; Comis R; Ginsberg S; Kohn L; Fitzpatrick A; Rubert M; Scalzo T
    Cancer Treat Rep; 1981; 65(7-8):647-50. PubMed ID: 6454483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
    Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
    Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of chlorozotocin in leukemia and other hematologic malignancies.
    Pavlovsky S; Woolley PV; Garay G; Scaglione C; Hoth D; Schein PS
    Cancer Treat Rep; 1981; 65(11-12):1109-11. PubMed ID: 6457686
    [No Abstract]   [Full Text] [Related]  

  • 18. Chlorozotocin: phase II evaluation in patients with myeloma.
    Cornell CJ; Pajak TF; McIntyre OR
    Cancer Treat Rep; 1984 Apr; 68(4):685-6. PubMed ID: 6231990
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I evaluation of chlorozotocin: single dose every six weeks.
    Taylor S; Belt RJ; Haas CD; Stephens RL; Hoogstraten B
    Cancer; 1980 Dec; 46(11):2365-8. PubMed ID: 6449279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.
    Talley RW; Samson MK; Brownlee RW; Samhouri AM; Fraile RJ; Baker LH
    Eur J Cancer (1965); 1981 Mar; 17(3):337-43. PubMed ID: 6455296
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.